Cargando…

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

In the last two years, clinical trials with blocking antibodies to the negative checkpoint regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple negative checkpoint regulators protect the host against autoimmune reactions but also restrict the ability of T cells to ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Mercier, Isabelle, Lines, J. Louise, Noelle, Randolph J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544156/ https://www.ncbi.nlm.nih.gov/pubmed/26347741 http://dx.doi.org/10.3389/fimmu.2015.00418

Ejemplares similares

A New VISTA on combination therapy for negative checkpoint regulator blockade
por: Deng, Jie, et al.
Publicado: (2016)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4
por: Fisher, Katie, et al.
Publicado: (2023)

Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese
por: Huang, Xiaosheng, et al.
Publicado: (2021)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis
por: Pereira, Joseph A., et al.
Publicado: (2023)

Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?
por: Lanuza, Pilar M., et al.
Publicado: (2020)

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types
por: Oyewole-Said, Damilola, et al.
Publicado: (2020)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia
por: Broglie, Larisa, et al.
Publicado: (2019)

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
por: Rodriguez, B. Leticia, et al.
Publicado: (2023)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
por: Liu, Jian-Nan, et al.
Publicado: (2020)

Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
por: Schneider, Helga, et al.
Publicado: (2014)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
por: Hu, Yun, et al.
Publicado: (2022)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1
por: Mathew, Divij, et al.
Publicado: (2021)

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
por: Kahlmeyer, Andreas, et al.
Publicado: (2019)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023)

BATF Potentially Mediates Negative Regulation of PD-1/PD-Ls Pathway on T Cell Functions in Mycobacterium tuberculosis Infection
por: Liu, Qianqian, et al.
Publicado: (2019)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i72vblmopee7snk6vntnotactb